Flinton Capital Management LLC increased its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 6.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,304 shares of the biotechnology company’s stock after buying an additional 144 shares during the quarter. Flinton Capital Management LLC’s holdings in Ascendis Pharma A/S were worth $265,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. NumerixS Investment Technologies Inc acquired a new position in shares of Ascendis Pharma A/S during the 1st quarter worth approximately $94,000. First Trust Advisors LP acquired a new position in shares of Ascendis Pharma A/S during the 2nd quarter worth approximately $215,000. SG Americas Securities LLC raised its position in shares of Ascendis Pharma A/S by 12.6% during the 1st quarter. SG Americas Securities LLC now owns 2,088 shares of the biotechnology company’s stock worth $246,000 after purchasing an additional 234 shares during the last quarter. LPL Financial LLC raised its position in shares of Ascendis Pharma A/S by 6.2% during the 2nd quarter. LPL Financial LLC now owns 2,233 shares of the biotechnology company’s stock worth $257,000 after purchasing an additional 131 shares during the last quarter. Finally, Financial Counselors Inc. acquired a new position in shares of Ascendis Pharma A/S during the 1st quarter worth approximately $273,000.
NASDAQ ASND opened at $96.19 on Friday. Ascendis Pharma A/S has a 52 week low of $53.21 and a 52 week high of $133.96. The company has a 50-day moving average price of $110.04 and a two-hundred day moving average price of $116.50. The company has a debt-to-equity ratio of 0.05, a quick ratio of 11.59 and a current ratio of 11.59.
Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Wednesday, August 28th. The biotechnology company reported ($1.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by ($0.08). The firm had revenue of $3.61 million during the quarter, compared to analysts’ expectations of $0.68 million. Ascendis Pharma A/S had a negative net margin of 932.52% and a negative return on equity of 35.99%. Equities research analysts expect that Ascendis Pharma A/S will post -5.31 earnings per share for the current fiscal year.
Several brokerages recently issued reports on ASND. Zacks Investment Research upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, August 27th. Wedbush set a $191.00 target price on shares of Ascendis Pharma A/S and gave the stock a “buy” rating in a research note on Tuesday. Canaccord Genuity lifted their target price on shares of Ascendis Pharma A/S from $133.00 to $144.00 and gave the stock a “buy” rating in a research note on Friday, May 31st. BidaskClub cut shares of Ascendis Pharma A/S from a “sell” rating to a “strong sell” rating in a research note on Thursday, September 12th. Finally, JPMorgan Chase & Co. upped their price target on shares of Ascendis Pharma A/S from $143.00 to $152.00 and gave the stock an “overweight” rating in a research report on Thursday, August 29th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $148.71.
Ascendis Pharma A/S Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Read More: After-Hours Trading
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.